44
Participants
Start Date
July 31, 2017
Primary Completion Date
November 30, 2025
Study Completion Date
May 31, 2027
Inotuzumab Ozogamicin
"Inotuzumab ozogamicin, IV, 28 day cycles~Phase 1 dosages:~Dose Level -2 (0.1 mg/m\^2)~Dose Level -1 (0.2 mg/m\^2)~Dose Level 0 (0.3 mg/m\^2)~Dose Level 1 (0.4 mg/m\^2)~Dose Level 2 (0.5 mg/m\^2)~Dose Level 3 (0.6 mg/m\^2)"
ACTIVE_NOT_RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
The James Cancer Hospital and Solove Research Institute, Columbus
ACTIVE_NOT_RECRUITING
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland
RECRUITING
The University of Kansas Cancer Center, Westwood
RECRUITING
University of Nebraska Medical Center, Omaha
RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland
Leland Metheny
OTHER